Exposure of rats to continuous light attenuates melatonin production and results in hypertension development. This study investigated whether hypertension induced by continuous light (24 hours/day) exposure induces heart and aorta remodelling and if these alterations are prevented by melatonin or angiotensin converting enzyme inhibitor captopril. Four groups of 3-month-old male Wistar rats (10 per group) were treated as follows for six weeks: untreated controls, exposed to continuous light, light-exposed, and treated with either captopril (100 mg/kg/day) or melatonin (10 mg/kg/day). Exposure to continuous light led to hypertension, left ventricular (LV) hypertrophy and fibrosis, and enhancement of the oxidative load in the LV and aorta. Increase in systolic blood pressure by continuous light exposure was prevented completely by captopril and partially by melatonin. Both captopril and melatonin reduced the wall thickness and cross-sectional area of the aorta and reduced the level of oxidative stress. However, only captopril reduced LV hypertrophy development and only melatonin reduced LV hydroxyproline concentration in insoluble and total collagen in rats exposed to continuous light. In conclusion, captopril prevented LV hypertrophy development in the continuous light-induced hypertension model, while only melatonin significantly reduced fibrosis. This antifibrotic action of melatonin may be protective in hypertensive heart disease.

3rd Clinic of Medicine School of Medicine Comenius University 83305 Bratislava Slovakia

Center of Excellence NOREG 81372 Bratislava Slovakia ; Institute of Normal and Pathological Physiology Slovak Academy of Sciences 81371 Bratislava Slovakia

Department of Pathophysiology School of Medicine Comenius University Sasinkova 4 81372 Bratislava Slovakia

Department of Pathophysiology School of Medicine Comenius University Sasinkova 4 81372 Bratislava Slovakia ; 3rd Clinic of Medicine School of Medicine Comenius University 83305 Bratislava Slovakia ; Institute of Experimental Endocrinology Slovak Academy of Sciences 83305 Bratislava Slovakia ; Center of Excellence NOREG 81372 Bratislava Slovakia

Department of Pathophysiology School of Medicine Comenius University Sasinkova 4 81372 Bratislava Slovakia ; Center of Excellence NOREG 81372 Bratislava Slovakia

Department of Pathophysiology School of Medicine Comenius University Sasinkova 4 81372 Bratislava Slovakia ; Institute of Molecular Biomedicine School of Medicine Comenius University 81372 Bratislava Slovakia

Department of Physiology School of Medicine Charles University 50038 Hradec Kralove 1 Czech Republic

Institute of Experimental Endocrinology Slovak Academy of Sciences 83305 Bratislava Slovakia ; Center of Excellence NOREG 81372 Bratislava Slovakia

Institute of Molecular Biomedicine School of Medicine Comenius University 81372 Bratislava Slovakia

Zobrazit více v PubMed

Reiter RJ, Manchester LC, Fuentes-Broto L, Tan D. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. Journal of Hypertension. 2010;28(1):S7–S12. PubMed

Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. Journal of Hypertension. 2010;28(supplement 1):S1–S6. PubMed

Simko F, Matuskova J, Luptak I, et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sciences. 2004;74(10):1211–1224. PubMed

Simko F, Pelouch V, Torok J, et al. Protein remodeling of the heart ventricles in hereditary hypertriglyceridemic rat: effect of ace-inhibition. Journal of Biomedical Science. 2005;12(1):103–111. PubMed

Mandarim-de-Lacerda CA, Pereira LMM. Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histology and Histopathology. 2004;19(3):727–733. PubMed

Simko F. Statins: a perspective for left ventricular hypertrophy treatment. European Journal of Clinical Investigation. 2007;37(9):681–691. PubMed

Kyselovic J, Krenek P, Wibo M, Godfraind T. Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. The British Journal of Pharmacology. 2001;134(7):1516–1522. PubMed PMC

Simko F, Reiter RJ, Pechanova O, Paulis L. Experimental models of melatonin-deficient hypertension. Frontiers in Bioscience. 2013;18(2):616–625. PubMed

Ozturk M, Ozler M, Kurt YG, et al. Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity. Journal of Pineal Research. 2011;50(1):89–96. PubMed

Grossini E, Molinari C, Uberti F, Mary DASG, Vacca G, Caimmi PP. Intracoronary melatonin increases coronary blood flow and cardiac function through β-adrenoreceptors, MT1/MT2 receptors, and nitric oxide in anesthetized pigs. Journal of Pineal Research. 2011;51(2):246–257. PubMed

Samimi-Fard S, Abreu-Gonzalez P, Dominguez-Rodriguez A, Jimenez-Sosa A. A case-control study of melatonin receptor type 1A polymorphism and acute myocardial infarction in a Spanish population. Journal of Pineal Research. 2011;51(4):400–404. PubMed

Zeman M, Herichova I. Melatonin and clock genes expression in the cardiovascular system. Frontiers in Bioscience. 2013;1(5):743–753. PubMed

Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. Journal of Pineal Research. 2007;42(4):319–322. PubMed

Tengattini S, Reiter RJ, Tan D, Terron MP, Rodella LF, Rezzani R. Cardiovascular diseases: protective effects of melatonin. Journal of Pineal Research. 2008;44(1):16–25. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, Kaski JC, Reiter RJ. Melatonin and circadian biology in human cardiovascular disease. Journal of Pineal Research. 2010;49(1):14–22. PubMed

Paulis L, Šimko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiological Research. 2007;56(6):671–684. PubMed

Hoffman RA, Reiter RJ. Rapid pinealectomy in hamsters and other small rodents. The Anatomical Record. 1965;153(1):19–21. PubMed

Cunnane SC, Manku MS, Oka M, Horrobin DF. Enhanced vascular reactivity to various vasoconstrictor agents following pinealectomy in the rat: role of melatonin. Canadian Journal of Physiology and Pharmacology. 1980;58(3):287–293. PubMed

Zanoboni A, Zanoboni-Muciaccia W. Experimental hypertension in pinealectomized rats. Life Sciences. 1967;6(21):2327–2331. PubMed

Brown GM, Bar-Or A, Grossi D, Kashur S, Johannson E. Urinary 6-sulphatoxymelatonin, an index of pineal function in the rat. Journal of Pineal Research. 1991;10(3):141–147. PubMed

Tan DX, Chen LD, Poeggeler B, et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine Journal. 1993;1:157–160.

Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochimica Polonica. 2007;54(1):1–9. PubMed

Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. Journal of Pineal Research. 2011;51(1):1–16. PubMed

Reiter RJ, Tan DX. Melatonin: a multitasking molecule. Progress in Brain Research. 2010;181:127–151. PubMed

Rezzani R, Porteri E, de Ciuceis C, et al. Effects of melatonin and pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension. 2010;55(6):1373–1380. PubMed

Reiter RJ, Tan D, Korkmaz A. The circadian melatonin rhythm and its modulation: possible impact on hypertension. Journal of Hypertension. 2009;27(supplement 6):S17–S20. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardiovascular disease: myth or reality? Revista Espanola de Cardiologia. 2012;65(3):215–218. PubMed

Paulis L, Matuskova J, Adamcova M, et al. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. Acta Physiologica. 2008;194(1):45–55. PubMed

Benova T, Viczenczova C, Radosinska J, et al. Melatonin attenuates hypertension-related proarrhythmic myocardial maladaptation of connexin-43 and propensity of the heart to lethalarrhythmias. Canadian Journal of Physiology and Pharmacology. 2013;91(8):633–639. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Reiter RJ. Prognostic value of nocturnal melatonin levels as a novel marker in patients with ST-segment elevation myocardial infarction. The American Journal of Cardiology. 2006;97(8):1162–1164. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Clinical aspects of melatonin in the acute coronary syndrome. Current Vascular Pharmacology. 2009;7(3):367–373. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Reiter RJ. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. Journal of Pineal Research. 2012;53(3):319–323. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Arroyo-Ucar E, Avanzas P, Reiter RJ. Global left ventricular longitudinal strain is associated with decreased melatonin levels in patients with acute myocardial infarction: a two-dimensional speckle tracking study. Biomarkers. 2013;18(4):310–313. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC, Reiter RJ, Jimenez-Sosa A. A unicenter, randomized, double-blind, parallel-group, placebo-controlled study of Melatonin as an Adjunct in patients with acute myocaRdial Infarction undergoing primary Angioplasty. The Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty (MARIA) trial: study design and rationale. Contemporary Clinical Trials. 2007;28(4):532–539. PubMed

Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Melatonin and cardioprotection in the acute myocardial infarction: a promising cardioprotective agent. International Journal of Cardiology. 2012;158(2):309–310. PubMed

Repova-Bednarova K, Aziriova S, Hrenak J. Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. Physiological Research. 2013;62(supplement 1):S135–S141. PubMed

Bernátová I, Pecháňová O, Pelouch V, Šimko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. Journal of Molecular and Cellular Cardiology. 2000;32(2):177–185. PubMed

Simko F, Pechanova O, Pelouch V, et al. Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. Journal of Hypertension. 2009;27(supplement 6):S5–S10. PubMed

Pelouch V, Milerova M, Ostadal B, Samánek M, Hucín B. Protein profiling of human atrial and ventricular musculature: the effect of normoxaemia and hypoxaemia in congenital heart diseases. Physiological Research. 1993;42(4):235–242. PubMed

Pelouch V, Milerova M, Ostadal B, Hucin B, Samanek M. Differences between atrial and ventricular protein profiling in children with congenital heart disease. Molecular and Cellular Biochemistry. 1995;147(1–4):43–49. PubMed

Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clinical Biochemistry. 1996;29(3):225–229. PubMed

Munch G, Keis R, Wessels A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA1. European Journal of Clinical Chemistry and Clinical Biochemistry. 1997;35(9):669–677. PubMed

Bhatwadekar AD, Ghole VS. Rapid method for the preparation of an AGE-BSA standard calibrator using thermal glycation. Journal of Clinical Laboratory Analysis. 2005;19(1):11–15. PubMed PMC

Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International. 1996;49(5):1304–1313. PubMed

Lang JK, Gohil K, Packer L. Simultaneous determination of tocopherols, ubiquinols, and ubiquinones in blood, plasma, tissue homogenates, and subcellular fractions. Analytical Biochemistry. 1986;157(1):106–116. PubMed

Kucharská J, Gvozdjáková A, Šimko F. Simvastatin decreased coenzyme Q in the left ventricle and skeletal muscle but not in the brain and liver in L-NAME-induced hypertension. Physiological Research. 2007;56(supplement 2):S49–S54. PubMed

Zeman M, Dulková K, Bada V, Herichová I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sciences. 2005;76(16):1795–1803. PubMed

Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nature Reviews Neuroscience. 2001;2(7):521–526. PubMed

Scheer FAJL, van Montfrans GA, van Someren EJW, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004;43(2):192–197. PubMed

Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Pressure. 2003;12(1):19–24. PubMed

Simko F, Pechanova O, Pelouch V, et al. Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. Journal of Hypertension. 2010;28(supplement 1):S13–S18. PubMed

Pechánová O, Zicha J, Paulis L, et al. The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. European Journal of Pharmacology. 2007;561(1–3):129–136. PubMed

Paulis L, Pechanova O, Zicha J, et al. Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-L-arginine-methyl ester hypertensive rats. Journal of Hypertension. 2009;27(supplement 6):S11–S16. PubMed

Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension. 2004;43(4):716–719. PubMed

Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiological Research. 2000;49(1):37–46. PubMed

Simko F. Is NO the king? Pathophysiological benefit with uncertain clinical impact [editorial] Physiological Research. 2007;56(supplement 2):S1–S6. PubMed

Karppanen H, Lahovaara S, Männistö P, Vapaatalo H. Plasma renin activity and in vitro synthesis of aldosterone by the adrenal glands of rats with spontaneous, renal, or pinealectomy induced hypertension. Acta Physiologica Scandinavica. 1975;94(2):184–188. PubMed

Milosievic V, Trifunovic S, Sekulic M, et al. Chronic exposure to constant light affects morphology and secretion of adrenal zona fascikulata cells in female rats. General Physiology and Biophysics. 2005;24(3):299–309. PubMed

Li H, Kang Y, Yu L, Xu H, Zhao H. Melatonin reduces blood pressure in rats with stress-induced hypertension viaGABAA receptors. Clinical and Experimental Pharmacology and Physiology. 2009;36(4):436–440. PubMed

Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Advances in Medical Sciences. 2007;52:11–28. PubMed

Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Journal of Pineal Research. 2011;50(3):261–266. PubMed

Simko F, Simko J, Fabryova M. ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovascular Drugs and Therapy. 2003;17(3):287–290. PubMed

Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril

The Impact of microRNAs in Renin-Angiotensin-System-Induced Cardiac Remodelling

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril